<DOC>
	<DOCNO>NCT02695446</DOCNO>
	<brief_summary>The primary objective study evaluate skin plasma concentration minocycline subject undergoing treatment acne vulgaris oral extend release minocycline . Acne lesion count safety/tolerance treatment also evaluate .</brief_summary>
	<brief_title>Administration Oral Extended Release Minocycline Assessment Skin Plasma Concentrations Minocycline</brief_title>
	<detailed_description>This open label , non randomize , interventional pilot study evaluate plasma skin level minocycline 10 subject moderate severe acne vulgaris . Subjects non inflammatory acne nodular acne enrol . Subjects oral extend release minocycline regimen 2mg/kg day 4 week . Steady state level minocycline plasma skin determine .</detailed_description>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Otherwise healthy male female subject 14 40 year age Moderate severe inflammatory facial acne vulgaris ( EGSA score 35 ) Subjects use oral topical antibiotic product least 30 day prior study entry willing refrain use oral topical antibiotic duration study participation Subjects currently use willing refrain use topical acne product duration study participation Mild , noninflammatory nodular acne vulgaris Have current previous skin cancer Have history skin disease presence skin condition PI believe would interfere study Females report pregnant , plan pregnancy study period breastfeed Have condition factor PI believe may affect response skin interpretation result Participation clinical study within previous 30 day plan concurrent participation study</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>